Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study

BACKGROUND: The safety of intraperitoneally administrated paclitaxel (op PTX) was demonstrated in the phase I trial of ip PTX combined with conventional systemic chemotherapy for colorectal cancer with peritoneal carcinomatosis. Moreover, the median survival time was 29.3 months, which was longer th...

Descripción completa

Detalles Bibliográficos
Autores principales: Murono, Koji, Yokoyama, Yuichiro, Nozawa, Hiroaki, Sasaki, Kazuhito, Emoto, Shigenobu, Matsuzaki, Hiroyuki, Kashiwabara, Kosuke, Ishigami, Hironori, Gohda, Yoshimasa, Yamaguchi, Hironori, Kitayama, Joji, Ishihara, Soichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282041/
https://www.ncbi.nlm.nih.gov/pubmed/37340243
http://dx.doi.org/10.1007/s00384-023-04434-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282041/
https://www.ncbi.nlm.nih.gov/pubmed/37340243
http://dx.doi.org/10.1007/s00384-023-04434-5

Ejemplares similares